Table 1.

Selected isolates of Aspergillus spp. used in this study

Species or study isolate no.Source no.Provider (reference no.)
A. fumigatus
 1NCPF 7101 (AF210)a,b D. Denning (4, 5)
 2NCPF 7102 (AF294)a,b D. Denning (4)
 3NCPF 7098 (AF71)a,b,c D. Denning (4, 24)
 4NCPF 7097 (AF65)a,b D. Denning (4, 24)
 5NCPF 7100 (AF91)c,d D. Denning (4, 5, 24)
 6NCPF 7099 (AF72)d D. Denning (4, 5)
 7AZ 606e P. Verweij (NAf)
 8NIH 4215d T. Walsh (NA)
 9A 1604a,b A. Espinel-Ingroff (10, 25)
A. flavus
 10A 1340a A. Espinel-Ingroff (7)
 11A 830a A. Espinel-Ingroff (7)
 12A 003a,b A. Espinel-Ingroff (7, 10, 25)
A. terreus
 13A 122a A. Espinel-Ingroff (7)
 14NIH 961290a T. Walsh (NA)
 15NIH 95644a T. Walsh (NA)
  • a Low itraconazole MICs (≤1.0 μg/ml) by M38-P, Etest, or other methods described in corresponding publication(s).

  • b Animals and patients responded to itraconazole treatment (isolates had low itraconazole MICs [<1.0 μg/ml]).

  • c These two isolates also had either a good (isolate 3) or decreased (isolate 5) response to posaconazole in a murine model.

  • d Animals and patients did not respond to itraconazole treatment (isolates had high itraconazole MICs [>8 μg/ml]).

  • e Voriconazole-resistant laboratory mutant.

  • f NA, not available.